Peptide compounding sits at the center of US peptide-access policy in 2026. The April 23, 2026 removal of twelve peptides from FDA Category 2 (including BPC-157, GHK-Cu injectable, TB-500, KPV, MOTS-c, Semax, Selank, AOD-9604, CJC-1295, ipamorelin, and Epitalon) opened a 90-day window before the July 23-24 PCAC meeting where seven of them went to a vote for 503A bulks list eligibility.
The July 23-24 PCAC outcome reshapes the compounding pathway: 6 of 7 peptides recommended over two days, all against the FDA career-staff position. Day 1 (Thursday July 23): BPC-157 (8-6 with 1 abstention), KPV (8-6 with 1 abstention), TB-500 (8-6), and MOTS-c (7-5 with 2 abstentions). Day 2 (Friday July 24): Semax (8-5) and Epitalon (7-4) recommended; Emideltide/DSIP rejected. PCAC recommendations are advisory; FDA rulemaking to add the peptides to the bulks list takes approximately 6-18 months per substance from the date the agency decides to act.
On the GLP-1 side, the FDA's April 30, 2026 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list closed for comment June 29. Telehealth platforms (Hims & Hers, LifeMD) migrated to branded supply via Novo and Lilly partnerships through Q1-Q2 2026; Hims & Hers acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capabilities, positioning for the PCAC outcome. Analyst Jonah Lupton projects Hims could generate $10-19B in annual peptide-related revenue by 2030 if it captures 4-5% of the combined GLP-1 and non-GLP-1 peptide markets.
Enforcement layered alongside reclassification. The FDA issued 50+ warning letters to peptide vendors and compounders in 2024-2025; the Alabama Board of Medical Examiners (May 26, 2026) and Ohio State Board of Pharmacy (February 2026) added state-level prescribing restrictions. The EVEXIAS/FarmaKeio April 2024 APA lawsuit against the FDA set the legal counterpush in motion. Stories here cover the compounding-pharmacy regulatory thread end to end. See [[pcac]], [[503a]], [[503b]], and [[gray-market]] for adjacent threads.
The FDA Pharmacy Compounding Advisory Committee (PCAC) peptide meeting sits four days away, with the written-comment docket FDA-2025-N-6895 closing at 11:59 PM ET on Wednesday July 22, 2026. The two-day meeting opens Thursday July 23 and closes Friday July 24 at FDA's White Oak Campus in Silver Spring, Maryland. Day 1 (Thursday) reviews BPC-157, KPV, TB-500, and MOTS-c for 503A bulks-list eligibility. Day 2 (Friday) reviews DSIP (Emideltide), Semax, and Epitalon. FDA career-staff briefing documents released June 29-30 recommended against adding any of the seven peptides to the 503A Bulks List, citing immunogenicity concerns, heavy-metal and microbial contamination in compounding-channel samples, mislabeled contents, and thin 503A historical use. The written-comment docket has attracted filings from compounding-pharmacy industry groups (Alliance for Pharmacy Compounding, National Community Pharmacists Association, Outsourcing Facilities Association), consumer-safety voices (Public Citizen, Institute for Safe Medication Practices, Partnership for Safe Medicines), academic researchers (UC Davis's Paul Knoepfler), and individual physicians and patients across both sides. A 'no' vote does not re-ban anything (the seven peptides came off Category 2 April 23), but a 'yes' vote requires FDA rulemaking (typically 6-18 months) before compounding pharmacies can act on it.
The FDA Pharmacy Compounding Advisory Committee (PCAC) written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026, five days from today. Late submissions after Wednesday will remain on the public record but will not reach panelists before the July 23-24 meeting at FDA's White Oak Campus in Silver Spring, Maryland. Day 1 (Thursday July 23) reviews BPC-157, KPV, TB-500, and MOTS-c for 503A bulks-list eligibility. Day 2 (Friday July 24) reviews DSIP (Emideltide), Semax, and Epitalon. FDA career-staff briefing documents released June 29-30 recommended against adding any of the seven peptides, citing immunogenicity concerns, heavy-metal and microbial contamination in compounding-channel samples, mislabeled contents, and thin 503A historical use. HHS Secretary Robert F. Kennedy Jr.'s public push for expanded peptide access runs counter to the FDA career-staff recommendation, and at least seven of the eight new PCAC panelists named June 29 have ties to peptide-related businesses (per STAT News reporting). A 'no' vote does not re-ban anything (the seven peptides came off Category 2 April 23), but a 'yes' vote requires FDA rulemaking (typically 6-18 months) before compounding pharmacies can act on it.
The FDA Pharmacy Compounding Advisory Committee (PCAC) meeting on seven research peptides is six days out. The written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET Wednesday July 22, one day before the meeting opens July 23-24 at White Oak. Day 1 (July 23) covers BPC-157, KPV, TB-500, and MOTS-c. Day 2 (July 24) covers DSIP (Emideltide), Semax, and Epitalon. FDA career-staff briefing documents released June 29-30 concluded all seven peptides have insufficient evidence for 503A bulks-list eligibility, citing immunogenicity questions, heavy-metal and microbial contamination in compounding-channel samples, mislabeled contents, and thin 503A historical use. HHS Secretary Robert F. Kennedy Jr.'s public push for expanded peptide access runs counter to the career-staff recommendation, and at least seven of the eight new PCAC panelists named June 29 have documented ties to peptide-related businesses (per STAT News reporting). Comments filed by the July 9 member-review cutoff are already in the reading packet; comments filed between July 10 and July 22 will be on the record but reach members after their initial review. A 'no' vote does not re-ban anything (the seven peptides came off Category 2 April 23), but a 'yes' vote requires FDA rulemaking (typically 6-18 months) before compounding pharmacies can act on it.
NPR published a nationally syndicated feature Wednesday July 8, 2026 on the FDA effort to expand compounding-pharmacy access to popular peptides including TB-500, BPC-157, and MOTS-c ahead of the July 23-24 PCAC vote. The reporting placed three lines side by side: HHS Secretary Robert F. Kennedy Jr. extolled peptide benefits in a Joe Rogan interview earlier this year and promised to reverse Biden-era restrictions preventing US compounding pharmacies from making them; the Institute for Safe Medication Practices told NPR 'these peptides really do not have established effectiveness, so the only thing you have is risk'; and NPR noted many members of the FDA advisory committee have ties to the peptide industry and work for clinics that offer injectable peptides. The piece syndicated across dozens of member stations (KUAF, NSPR, WLRN, Prairie Public, HPPR, WVXU, KALW, WKNO, KUNC among them), pushing the panel-composition story past trade press (Endpoints, STAT, FiercePharma) and academic-scientist voices (Knoepfler in Washington Post) into general-audience mainstream media two weeks before the vote.
Writing in STAT on July 6, Jerome Adams, the 20th US Surgeon General, argues the FDA should reject both an outright ban and unrestricted access ahead of the July 23-24 Pharmacy Compounding Advisory Committee vote. He proposes allowing select peptides through licensed 503A pharmacies under strict quality controls, requiring clinician evaluation and informed-consent documentation, and mandating real-world outcome tracking to build the safety and efficacy data that gray-market 'research use only' products never generate. The piece notes acting FDA commissioner Kyle Diamantas and a follow-up review expected before February 2027.
Registration for oral testimony at the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23-24, 2026 closes Tuesday June 30, 2026 — one day from this Monday digest. The two-day meeting at the FDA White Oak campus in Silver Spring, Maryland (with virtual attendance option) will vote on 503A bulks list eligibility for seven peptides: BPC-157, KPV, TB-500, and MOTS-c on Day 1 (July 23); Emideltide (delta sleep-inducing peptide / DSIP), Semax, and Epitalon on Day 2 (July 24). Pharmacist-facing guidance in Pharmacy Times (Annie Lambert, PharmD, BCSCP, Wolters Kluwer clinical program manager for compliance solutions, published two days ago) advised compounding pharmacies to prepare for the post-PCAC market regardless of which specific peptides receive affirmative votes. Written comments to docket FDA-2025-N-6895 remain open through July 22 at 11:59 PM ET. The seven peptides came off the FDA's Category 2 'do not compound' list effective April 23, 2026; PCAC affirmative votes plus FDA acceptance are needed for formal 503A bulks list addition. Hims & Hers (HIMS), LifeMD, Henry Meds, and the broader telehealth-peptide platform space have priced in some affirmative outcomes (Barclays $39 HIMS PT, June 17; Leerink Market Perform reiteration this past week).
The FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 at the agency's White Oak campus (Silver Spring, Maryland) reaches its first procedural cutoff next Tuesday: June 30, 2026 is the deadline to register for oral testimony in the public-comment portion of the meeting. Written comments to docket FDA-2025-N-6895 at regulations.gov must arrive by 11:59 PM ET July 22, 2026 (one day before the meeting opens). The Committee will discuss BPC-157, KPV, TB-500, and MOTS-C on Day 1 (July 23) and Emideltide/DSIP, Semax, and Epitalon on Day 2 (July 24). All seven peptides came off FDA Category 2 effective April 23, 2026. PCAC recommendations are advisory: the agency makes the final 503A bulks list decision, and the Hims & Hers (HIMS) stock breakout above $30 reflected market consensus that the July vote will tilt toward eligibility. Lengea Law and PeptideClarity have both published prescriber-facing trackers ahead of the meeting.
Hims & Hers Health (NYSE: HIMS) broke above $30 on June 22, 2026 for the first time since April, finishing the month +36% — its best month since March — on rising investor confidence in the company's peptide platform ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting. Leerink called the PCAC meeting a key catalyst, framing peptides as Hims' next major product category supporting growth beyond 2027. FirstWave Fund CEO Jonah Lupton projected Hims could generate $10-19 billion in annual peptide-related revenue by 2030 if it captures 4-5% of the combined GLP-1 and non-GLP-1 peptide markets. Hims acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capabilities. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' signaling deeper wearable connectivity. The June 22-23 stock move reflects the broader market consensus that PCAC will reclassify the seven peptides under review (BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax, Epitalon) and open compounding-pharmacy supply channels.
The Ohio State Board of Pharmacy released a February 18, 2026 update to its peptide compounding guidance establishing state-specific requirements that layer on top of federal 503A rules. The Ohio guidance requires all compounded peptides to be prepared pursuant to a valid patient-specific prescription from an Ohio-licensed practitioner, with detailed prescription documentation and provider-verification protocols; pharmacies cannot compound peptides on the FDA list of substances withdrawn for safety or effectiveness reasons. The guidance followed late-2025 and early-2026 enforcement actions in which at least three Ohio pharmacies received consent agreements and fines for peptide compounding violations. Together with the Alabama Board of Medical Examiners' May 26 notice prohibiting non-FDA-approved peptide prescribing, Ohio's update establishes a clear state-level enforcement pattern ahead of the July 23-24 PCAC meeting.
Pharmacy Times hosted a CME-eligible virtual symposium May 19 (1:00-2:30 PM EDT) framing the post-RFK Jr. peptide moment for hospital and retail pharmacists. The agenda crossed the wellness-clinic side (BPC-157, TB-500, CJC-1295, GHK-Cu after the April 22 503A Category-2 removal) with the FDA-approved peptide side (semaglutide, tirzepatide, liraglutide, navepegritide, paltusotine) and walked attendees through the July 23-24 PCAC vote calculus and patient counseling around compounded GLP-1 risk.
A Bloomberg opinion piece published April 21 argues that the FDA's planned July 23-24 PCAC review of seven peptides (BPC-157, MOTS-c, KPV, among others) and RFK Jr.'s broader push to reclassify 14 of 19 Category 2 peptides doesn't give consumers the evidence-based safety and efficacy data they need. The piece frames the ongoing compounding debate as a consumer-protection gap that clinical trial evidence — not political reclassification — should fill.